Use of antihypertensive medications not associated with risk of contralateral breast cancer among women diagnosed with estrogen-receptor positive invasive breast cancer
Menée aux Etats-Unis et portant sur 359 cas et 391 témoins, cette étude évalue l'association entre l'utilisation de médicaments contre l'hypertension et le risque de second cancer primitif controlatéral chez des patientes ayant survécu à un cancer du sein invasif ER+
Background:Antihypertensive medications are widely used among adults in the U.S. and there is some evidence that certain classes may affect the risk of adverse breast cancer outcomes, but their impact on risk of second primary contralateral breast cancer is unclear. Methods:We used data from a population-based nested case-control study consisting of 359 women diagnosed with both a first primary breast cancer and a second primary contralateral breast cancer and 691 control women diagnosed with only a single breast cancer and individually matched to cases. Multivariate conditional logistic regression was used to estimate odds ratios and 95% confidence intervals for risks associated with ever, recency and duration of use for various antihypertensive medications. Results:No class of antihypertensive, including calcium channel blockers, β blockers, ACE inhibitors and diuretics, was associated with risk of second primary contralateral breast cancer. These results did not change materially in a sensitivity analysis restricted to women with a history of hypertension. Conclusions:Our findings do not support associations between use of various antihypertensives and CBC risk among women with estrogen receptor + breast cancer. Impact:The present study adds evidence to support the safety of commonly used antihypertensive medications among breast cancer survivors with respect to risk of second primary contralateral breast cancer.